Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women

HIV Infections Clinical Trial

Official title:

A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01539226
• Other study ID #: IPM 027
• Status: Completed
• Phase: N/A
• Start date: March 27, 2012
• Est. completion date: December 13, 2016

Study information

• Verified date: July 2022
• Source: International Partnership for Microbicides, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blind, randomised, placebo-controlled study to assess the safety and efficacy of a silicone elastomer vaginal matrix ring.

Description:

A multi center, randomized, double-blind, placebo=controlled safety and efficacy trial of a Dapivirine Vaginal Matrix Ring in healthy HIV-negative women.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1959
• Est. completion date: December 13, 2016
• Est. primary completion date: December 13, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Women > 18 and < 45 years of age, at screening, who can provide informed consent;

• Available for all visits and consent to follow all procedures scheduled for the trial;

• Self-reported sexually active (defined as an average of at least one penetrative penile-vaginal coital act per month for the last 3 months prior to screening);

• HIV-negative as determined by the HIV algorithm applied at screening and enrolment;

• On a stable form of contraception as defined within section 5.4 and willing to continue on stable contraception for the duration of the clinical trial, unless post-menopausal or surgically sterilised;

• Asymptomatic for genital infections at the time of enrolment (if a woman is diagnosed with any clinically significant curable STI, she must have initiated treatment at least 1 week prior to enrolment and have completed the full course of treatment);

• Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures (e.g., by home visit or telephone; or via family or close neighbour contacts); confidentiality to be maintained;

• Willing to refrain from participation in another research trial using drugs, vaccines, medical devices, microbicides or oral pre-exposure prophylaxis investigational drugs for the duration of the IPM 027 trial.

Exclusion Criteria:

• Currently pregnant or last pregnancy within 3 months prior to screening or intends to become pregnant during trial participation;

• Currently breast-feeding;

• Non-therapeutic injection drug use in the 12 months prior to screening;

• Participated in another research trial using drugs, medical devices, microbicides or oral pre-exposure prophylaxis agents within 60 days prior to screening;

• Previously participated or currently participating in any HIV vaccine trial;

• Untreated, clinically significant urogenital infections , e.g., urinary tract, or other sexually transmitted infections, or other gynaecological symptoms within 1 week prior to enrolment;

• Has a Grade 2 or higher pelvic examination finding, according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in Microbicide Studies;

• History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, diagnosed chronic and/or recurrent vulvovaginal candidiasis, urethral obstruction, incontinence or urge incontinence;

• Any gynaecological surgery within 90 days prior to screening;

• Any Grade 1 or higher baseline aspartate aminotransferase (AST), alanine transaminase (ALT), or platelet count, and any Grade 2 or higher baseline haematology, chemistry or urinalysis laboratory value according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events;

• Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex or a silicone elastomer;

• Any history of diabetes mellitus and chronic use of oral corticosteroid therapy; and any uncontrolled serious chronic or progressive disease;

• Cervical cytology at screening that requires cryotherapy, biopsy or treatment (other than for infection). Women with Grade 1 cervical cytology findings can be enrolled upon completion of the initial phase of evaluation if no current treatment is indicated (based on local standard of care for management of abnormal cervical cytology);

• Any condition(s) that, in the opinion of the investigator, might put the participant at risk, or interfere with the trial objectives or the participant's adherence to trial requirements.

Related Conditions & MeSH terms

• HIV Infections

Intervention

Combination Product:
• Placebo Vaginal Ring
Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
• Dapivirine Vaginal Ring, 25 mg
Dapivirine Vaginal Ring containing 25 mg of dapivirine

Locations

Country	Name	City	State
South Africa	Madibeng Centre for Research (MCR)	Brits
South Africa	Desmond Tutu HIV Foundation, Guinea Fowl Road, Sunnydale, Fish Hoek	Cape Town
South Africa	Ndlovu Medical Centre	Elandsdoorn	Limpopo
South Africa	Qhakaza Mbokodo	Ladysmith	Kwazulu Natal
South Africa	Prevention of HIV / AIDS (PHIVA) Project	Pinetown	KwaZulu Natal
South Africa	Maternal, Adolescent and Child Health (MatCH)	Plessislaer
Uganda	MRC/UVRI Uganda Research Unit on AIDS, Plot 51-59, Nakiwogo Road, PO BOX 49	Masaka

Sponsors (1)

Lead Sponsor	Collaborator
International Partnership for Microbicides, Inc.

Countries where clinical trial is conducted

South Africa,  Uganda, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HIV-1 Seroconversion According to Comprehensive HIV Testing Algorithm.	HIV-1 seroconversion measured by rapid and specialised laboratory testing according to the comprehensive HIV testing algorithm.	24 months
Primary	All Adverse Events	Self-reports, physical examination, gynaecological assessments, including pelvic/speculum examination, laboratory tests and other indicated investigations. All AEs will be reported, regardless of grade or relatedness.	24 months
Secondary	The Incidence Rate of HIV-2 Seroconversion.	Rapid and specialised laboratory testing according to the comprehensive HIV testing algorithm in Appendix C of protocol.	24 months
Secondary	The Incidence of Curable STIs	The percentage of participants testing positive for any STI (gonorrhoea, chlamydia, trichomonas, syphilis) will be assessed.	24 months
Secondary	Percentage of Participants With Pregnancy in Each Trial Arm Over the IP Use Period;	The percentage of participants with pregnancies in each treatment group. For each treatment group, the numerator will include the number of participants that had a positive urine pregnancy test during the trial period.	24 months
Secondary	The Percentage of Women Who Report Adherence to the Use of the Vaginal Ring Inserted Once Every 4 Weeks Over the Trial Period;	Questionnaires and qualitative data regarding sexual behaviour and adherence to the use of a vaginal ring inserted once every 4 weeks over the trial period.; Dapivirine residual levels in used rings and dapivirine plasma concentrations are two objective measures of adherence to DVR ring use,	24 months
Secondary	The Percentage of Women Who Report the Use of the Vaginal Ring as Acceptable;	Questionnaires and qualitative data regarding the acceptability of use of a vaginal ring inserted once every 4 weeks over the trial period; Number of participants with positive response. Response of 'likely' or 'very likely' to the question: 'If in the future a vaginal ring was available that provided some protection against HIV, and it was similar to the one you used in this trial, how likely would you be to keep it inserted in your vagina every day?'	24 months
Secondary	The Percentage of Participants With HIV-1 Drug Resistance Mutations Among Participants Who Acquire HIV-1.	The analysis of HIV-1 drug resistance will be primarily descriptive in nature, and will depend on the pattern of resistance mutations observed in the HIV-1 seroconverters. The proportion of HIV-1 seroconverters with at least one HIV-1 drug resistant mutation will be presented overall, and by treatment arm, with corresponding 95% CIs.	24 months